Replimune Group, Inc. 10-K

Item 5. Market for registrant’s common equity, related stockholder matters and issuer purchases of equity securities Our common stock has been listed on the Nasdaq Global Select Market under the symbol “REPL” since July 20, 2018. Prior to that date, there was no public trading market for our common stock. Holders of common stock As of the close of business on May 31, 2026, there were approximately 5 holders of record of our common stock, based upon information received from our transfer agent. However, this number does not include beneficial owners whose shares were held of record by nominees or broker dealers. Dividend policy We have never declared or paid any dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, contractual restrictions, business prospects, general business conditions and other factors that our board of directors may deem relevant. Securities authorized for issuance under equity compensation plans Information regarding our equity compensation plans and the securities authorized for issuance thereunder is set forth herein under Part III, Item 12 below. Recent sales of unregistered securities There have been no unregistered sales of securities other than previously disclosed by us in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K. Purchases of equity securities by the Issuer and affiliated purchasers None. Performance Graph Not required. Item 6. Reserved